Former UCLA Decathlete Sentenced to 17.5 Years in Jail for Securities Fraud

Nov.22.2022
Former UCLA Decathlete Sentenced to 17.5 Years in Jail for Securities Fraud
Former UCLA decathlete sentenced to 210 months in prison for defrauding investors of over $45 million.

LOS ANGELES – A former decathlete from the University of California, Los Angeles who once competed for the Philippine national team was sentenced to 210 months in prison today for fraudulently raising over $45 million from investors. These investors were told their funds would be used to support a company marketing cannabis e-cigarettes.


David Joseph Bunevacz, 53 years old from the city of Calabasas, has been sentenced by US District Judge Dale S. Fischer to pay $35,267,851 in restitution. During today's sentencing hearing, Judge Fischer noted that Bunevacz had "bullied those who thought he was their friend," and that the severity of his actions cannot be measured solely in monetary terms.


Judge Fischer also found that even during the probationary period following his conviction in state court, Bunevacz continued to carry out his plan and concluded that "neither criminal conviction nor threat of imprisonment could persuade [Bunevacz] to become a law-abiding citizen.


On July 18th, Bunevacz admitted to committing securities fraud and telecommunications fraud. He has been in federal custody since his arrest on April 5th in connection to this case.


Going back to 2010, Bunevacz created various business entities, including CB Holding Group Corp. and Caesarbrutus LLC, which he claimed were involved in the marijuana industry and the sale of electronic cigarettes containing marijuana products such as CBD oil and THC.


Bunevacz reportedly lied to at least one investor about his supposed long-term partnership with a Chinese manufacturer of disposable e-cigarettes. According to court documents, he claimed to have obtained "pesticide-free raw material oil" that was sent to a laboratory for flavor infusion using a "proprietary custom process" to make vape flavoring smooth and discrete. He also provided fake documents such as bank statements, invoices, and purchase orders to support his claims of the company's success and need for investor funding.


Bunevacz did not use these funds to provide financial support for the operation of his business - despite the fact that some of his victims are currently experiencing serious financial difficulties. Instead, he diverted the vast majority of the funds to finance his own luxurious lifestyle, which includes a mansion in Calabasas, trips to Las Vegas, expensive jewelry and designer handbags, extravagant birthday parties for his daughter, and horses.


To create the appearance of conducting legitimate business activities for his company, Bunevacz registered various shell companies, including several with similar or identical names to legitimate marijuana businesses. To conceal his control over these shell companies and related bank accounts, Bunevacz listed other individuals, including his stepdaughter, as executives of the shell companies.


Bunevacz's blog praises his success as a former decathlete competing in the Philippines, and highlights appearances of his wife and daughter on a reality show. According to sworn statements submitted in support of the criminal prosecution, despite promoting his background, Bunevacz made efforts to conceal negative information from investors, such as his conviction for a felony in 2017 for illegally selling securities.


After an investor discovered a lawsuit against Bunevacz, the latter sent a forged version of a settlement agreement via email, claiming he had received $325,000 as part of the settlement. However, in reality, it was Bunevacz who agreed to pay $325,000 to settle the claim.


According to government records, Bunevacz raised approximately $45,227,266 from over 100 victim investors through his marijuana company. Judge Fischer found that Bunevacz caused approximately $35,267,851 in losses.


A prosecutor argued in a sentencing memorandum that "the violation of personal dignity, emotional harm, and lasting trauma caused by [Bunevacz] are reminiscent of the harm typically associated with violent crimes." "Furthermore, [Bunevacz] victimized over 100 individuals, causing harm on a scale rarely seen.


The Federal Bureau of Investigation, the Criminal Investigation Division of the Internal Revenue Service, and the Los Angeles County Sheriff's Department conducted an investigation into the matter. The Securities and Exchange Commission provided significant assistance. Assistant U.S. Attorney Alexander B. Schwab of the Major Frauds Section filed charges in this case.


Statement:


This article is based on third-party information that has been translated using machine translation, and is only intended for exchange and learning within the industry.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of its content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in the translation process, the translated article may not fully reflect the intended meaning of the original. Please refer to the original text for accuracy.


2FIRSTS maintains complete consistency with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The compilation of the information herein is copyrighted by the original media source and author. If infringement occurs, please contact us for prompt removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
The vaping rate among women aged 25 to 34 in Great Britain reached 18.3% in 2025, up from 13.7% in 2024 and 8.3% in 2020, according to data from the Office for National Statistics (ONS). The figure was the highest for this group since records began in 2014 and exceeded the 14.4% recorded among men of the same age. Adults aged 25 to 34 also overtook those aged 16 to 24 as the age group with the highest vaping prevalence. Overall, about 5.4 million adults in Great Britain used e-cigarettes in 2025, broadly unchanged from the previous year.
DATA
Oct.13